We'd be surprised if SI-BONE, Inc. (NASDAQ:SIBN) shareholders haven't noticed that the CEO & Director, Laura Francis, recently sold US$244k worth of stock at US$19.67 per share. However, the silver lining is that the sale only reduced their total holding by 3.2%, so we're hesitant to read anything much into it, on its own.
Our free stock report includes 2 warning signs investors should be aware of before investing in SI-BONE. Read for free now.SI-BONE Insider Transactions Over The Last Year
Notably, that recent sale by CEO & Director Laura Francis was not the only time they sold SI-BONE shares this year. They previously made an even bigger sale of -US$796k worth of shares at a price of US$17.60 per share. That means that even when the share price was below the current price of US$18.42, an insider wanted to cash in some shares. We generally consider it a negative if insiders have been selling, especially if they did so below the current price, because it implies that they considered a lower price to be reasonable. However, while insider selling is sometimes discouraging, it's only a weak signal. This single sale was just 10% of Laura Francis's stake.
SI-BONE insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!
Check out our latest analysis for SI-BONE
I will like SI-BONE better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.
Does SI-BONE Boast High Insider Ownership?
For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. It appears that SI-BONE insiders own 2.8% of the company, worth about US$23m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
What Might The Insider Transactions At SI-BONE Tell Us?
Insiders sold SI-BONE shares recently, but they didn't buy any. Looking to the last twelve months, our data doesn't show any insider buying. While insiders do own shares, they don't own a heap, and they have been selling. We're in no rush to buy! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing SI-BONE. Case in point: We've spotted 2 warning signs for SI-BONE you should be aware of.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGM:SIBN
SI-BONE
A medical device company, focuses on solving musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally.
Flawless balance sheet and slightly overvalued.
Similar Companies
Market Insights
Community Narratives


